Alan Korman Korman

List of Publications by Year
in descending order

35 papers	25,312 citations	172457 29 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	28717 citing authors

#	Article	IF	Citations
1	Safety, Activity, and Immune Correlates of Antiâ€“PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	27.0	10,727
2	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	27.0	3,776
3	Phase I Study of Single-Agent Antiâ€“Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology, 2010, 28, 3167-3175.	1.6	2,667
4	Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape. Cancer Research, 2012, 72, 917-927.	0.9	1,311
5	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4712-4717.	7.1	940
6	Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunology Research, 2013, 1, 32-42.	3.4	726
7	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3005-3010.	7.1	604
8	TIGIT and PD-1 impair tumor antigenâ€“specific CD8+ T cells in melanoma patients. Journal of Clinical Investigation, 2015, 125, 2046-2058.	8.2	603
9	In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human Primates. Cancer Immunology Research, 2014, 2, 846-856.	3.4	514
10	Checkpoint Blockade in Cancer Immunotherapy. Advances in Immunology, 2006, 90, 297-339.	2.2	498
11	FcÎ³Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell, 2015, 28, 285-295.	16.8	291
12	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunology Research, 2017, 5, 106-117.	3.4	236
13	Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy. Seminars in Oncology, 2010, 37, 533-546.	2.2	218
14	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology, 2018, 7, e1466769.	4.6	217
15	VISTA is an acidic pH-selective ligand for PSGL-1. Nature, 2019, 574, 565-570.	27.8	214
16	A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2013, 8, e63818.	2.5	204
17	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	46.4	201
18	Antiâ€“Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factorâ€“Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors. Clinical Cancer Research, 2009, 15, 1623-1634.	7.0	174

#	Article	IF	Citations
19	Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE, 2016, 11, e0161779.	2.5	172
20	Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy. Journal of Immunotherapy, 2010, 33, 225-235.	2.4	171
21	CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight, 2018, 3, .	5.0	137
22	Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4223-E4232.	7.1	121
23	Targeting DDR2 enhances tumor response to antiâ€“PD-1 immunotherapy. Science Advances, 2019, 5, eaav2437.	10.3	92
24	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research, 2020, 26, 5520-5533.	7.0	88
25	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. OncoImmunology, 2018, 7, e1421891.	4.6	57
26	Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. Cancer Research, 2021, 81, 2983-2994.	0.9	56
27	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. OncoImmunology, 2020, 9, 1843247.	4.6	48
28	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases, 2018, 21, 113-125.	3.9	46
29	Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models. OncoImmunology, 2018, 7, e1377873.	4.6	43
30	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 6709-6720.	7.0	32
31	Masterful Antibodies: Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 275-281.	3.4	31
32	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	8.2	25
33	Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
34	Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. Cancer Immunology Research, 2020, 8, 131-145.	3.4	21
35	Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. Journal of Immunology, 2017, 198, 1575-1584.	0.8	15